Table 68: Test 16. Index test (Transient elastography) versus practice guideline CFLD definition[†] to detect CFLD

Number of studies (Reference) Test 16. Transie	Study desig n nt elasto	N graph	Risk of bias y using Fibr	Inconsiste ncy oscan 5.5kPa	Indirectn ess cut off in a	Imprecisio n population o	Sensitivi ty % (95% CI) f adults and	Specific ity % (95% CI)	Positiv e likeliho od ratio (95% CI)	Negativ e Likeliho od ratio (95% CI)	AUROC	Quality
1 (Rath 2012)	Cohort study	136	no serious risk of bias	no serious inconsisten cy	no serious indirectne ss	no serious imprecisio n	52.7 (95% CI: 44.9- 58.9)*	82.3 (95% CI: 72.9- 89.7)*	2.97 (95% CI: 1.65- 5.70)*	0.58 (95% CI: 0.46- 0.76)*	0.68 (95% CI: 0.59- 0.77)	HIGH
Test 16. Subgroup analysis: Transient elastography using Fibroscan @ 5.5kPa cut off in a population of adults												
1 (Rath 2012)	Cohort study	61	no serious risk of bias	no serious inconsisten cy	no serious indirectne ss	no serious imprecisio n	55.2 (95% CI: 40.7- 66.8)*	78.1 (95% CI: 65.0- 88.7)*	2.52 (95% CI: 1.16- 5.89)*	0.57 (95% CI: 0.38- 0.91)*	0.69 (95% CI: 0.56- 0.81)	HIGH
Test 16. Subgroup analysis:Transient elastography using Fibroscan @ 5.5kPa cut off in a population of children												
1 (Rath 2012)	Cohort study	75	no serious risk of bias	no serious inconsisten cy	no serious indirectne ss	no serious imprecisio n	53.3 (95% CI: 43.2- 61.2)*	76.7 (95% CI: 61.4- 88.4)*	2.29 (95% CI: 1.12- 5.28)*	0.61 (95% CI: 0.44- 0.93)*	0.68 (95% CI: 0.56- 0.81)	HIGH

Abbreviations: AST: aminotransferase; ALT: alanine aminotransferase; AUROC: area under the curve; CFLD: cystic fibrosis liver disease; CI: confidence interval; kPA: kilopascal

†Diagnosis of CFLD was established according to published guidelines (Debray 2011) if least 2 of the following conditions on at least 2 consecutive examinations spanning a 1-year period were present: (i) Hepatomegaly (liver span >2 cm below the costal margin on the medioclavicular line) confirmed by ultrasound, (ii) 2 abnormal serum liver enzyme levels (ALT, AST, γGT > ULN), (iii) ultrasound abnormalities other than hepatomegaly (increased, heterogeneous echogenicity, nodularity, irregular margins).

* Calculated by the NGA technical team from data available in the study report